Tue, March 13, 2018
Mon, March 12, 2018
Fri, March 9, 2018
Thu, March 8, 2018
Wed, March 7, 2018
Tue, March 6, 2018
Mon, March 5, 2018
Fri, March 2, 2018
Thu, March 1, 2018
Wed, February 28, 2018
Tue, February 27, 2018
Mon, February 26, 2018
Fri, February 23, 2018

Alethia Young Maintained (BMRN) at Buy with Increased Target to $116 on, Mar 2nd, 2018


//stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-116-on-mar-2nd-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Alethia Young of Credit Suisse, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $113 to $116 on, Mar 2nd, 2018.

Alethia has made no other calls on BMRN in the last 4 months.



There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Alethia


  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $124 on, Friday, February 23rd, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $132 on, Friday, February 23rd, 2018
  • M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $125 on, Friday, February 23rd, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, February 23rd, 2018
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $102 on, Friday, February 23rd, 2018
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $129 on, Wednesday, January 24th, 2018
  • Liana Moussatos of "Wedbush" Upgraded from Hold to Buy on, Thursday, December 14th, 2017

Publication Contributing Sources